Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | GISTs offer a promising evidence base for biomarkers of response to therapy in sarcomas

Robin Jones, MD, The Royal Marsden Hospital, London, UK, comments on the biomarkers of response to therapy in sarcomas, highlighting the gastrointestinal stromal tumours as a model for developing effective biomarkers, and notes that ongoing trials are exploring new treatments for patients with disease progression on imatinib. Prof. Jones emphasizes the challenges of developing a single biomarker for complex and heterogeneous sarcomas, such as angiosarcoma, osteosarcoma, and leiomyosarcoma, and suggests that a combination of functional imaging markers and tumor tissue markers is needed. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.